Axel Polymers Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 8, 2025, 6:39 pm

Quick Insight

Axel Polymers Ltd, with a share price of ₹51.5 and a market capitalization of ₹43.8 Cr., presents a mixed financial picture. The high P/E ratio of 62.6 indicates richly valued stock, while the ROE of 1.13% and ROCE of 7.88% suggest relatively low returns on equity and capital employed. The OPM stands at 8.55%, reflecting modest operational efficiency. The company's leverage is notable, with borrowings of ₹34.08 Cr. and a P/BV ratio of 2.30x. The low ICR of 1.27x raises concerns about its ability to service debt. With a significant promoter holding of 61.16%, Axel Polymers Ltd. may need to focus on improving profitability and reducing leverage to enhance shareholder value.

Competitors of Axel Polymers Ltd

All Competitor Stocks of Axel Polymers Ltd

Quarterly Result

Last Updated: August 1, 2025, 6:50 am

Below is a detailed analysis of the quarterly data for Axel Polymers Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 11.70 Cr.. The value appears to be declining and may need further review. It has decreased from 14.33 Cr. (Mar 2025) to 11.70 Cr., marking a decrease of 2.63 Cr..
• For Expenses, as of Jun 2025, the value is 10.70 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.03 Cr. (Mar 2025) to 10.70 Cr., marking a decrease of 0.33 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.30 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.30 Cr..
• For OPM %, as of Jun 2025, the value is 8.55%. The value appears to be declining and may need further review. It has decreased from 23.03% (Mar 2025) to 8.55%, marking a decrease of 14.48%.
• For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.08 Cr..
• For Interest, as of Jun 2025, the value is 0.82 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.82 Cr..
• For Depreciation, as of Jun 2025, the value is 0.15 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.20 Cr. (Mar 2025) to 0.15 Cr., marking a decrease of 0.05 Cr..
• For Profit before tax, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 2.37 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 2.33 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 5.91% (Mar 2025) to 0.00%, marking a decrease of 5.91%.
• For Net Profit, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 2.23 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 2.19 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.05. The value appears to be declining and may need further review. It has decreased from 2.62 (Mar 2025) to 0.05, marking a decrease of 2.57.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:44 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:46 pm

Below is a detailed analysis of the balance sheet data for Axel Polymers Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 8.52 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 8.52 Cr..
• For Reserves, as of Mar 2025, the value is 6.62 Cr.. The value appears strong and on an upward trend. It has increased from 6.47 Cr. (Mar 2024) to 6.62 Cr., marking an increase of 0.15 Cr..
• For Borrowings, as of Mar 2025, the value is 34.08 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 25.67 Cr. (Mar 2024) to 34.08 Cr., marking an increase of 8.41 Cr..
• For Other Liabilities, as of Mar 2025, the value is 18.20 Cr.. The value appears to be improving (decreasing). It has decreased from 23.81 Cr. (Mar 2024) to 18.20 Cr., marking a decrease of 5.61 Cr..
• For Total Liabilities, as of Mar 2025, the value is 67.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 64.47 Cr. (Mar 2024) to 67.42 Cr., marking an increase of 2.95 Cr..
• For Fixed Assets, as of Mar 2025, the value is 10.18 Cr.. The value appears strong and on an upward trend. It has increased from 9.77 Cr. (Mar 2024) to 10.18 Cr., marking an increase of 0.41 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 57.24 Cr.. The value appears strong and on an upward trend. It has increased from 54.70 Cr. (Mar 2024) to 57.24 Cr., marking an increase of 2.54 Cr..
• For Total Assets, as of Mar 2025, the value is 67.42 Cr.. The value appears strong and on an upward trend. It has increased from 64.47 Cr. (Mar 2024) to 67.42 Cr., marking an increase of 2.95 Cr..

However, the Borrowings (34.08 Cr.) are higher than the Reserves (6.62 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Axel Polymers Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 1.83 (Mar 24) to 0.20, marking a decrease of 1.63.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 1.83 (Mar 24) to 0.20, marking a decrease of 1.63.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 3. It has decreased from 2.65 (Mar 24) to 0.86, marking a decrease of 1.79.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.77. It has increased from 17.60 (Mar 24) to 17.77, marking an increase of 0.17.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 17.77. It has increased from 17.60 (Mar 24) to 17.77, marking an increase of 0.17.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 91.68. It has decreased from 150.19 (Mar 24) to 91.68, marking a decrease of 58.51.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 4.82. This value is within the healthy range. It has decreased from 6.84 (Mar 24) to 4.82, marking a decrease of 2.02.
• For PBIT / Share (Rs.), as of Mar 25, the value is 4.16. This value is within the healthy range. It has decreased from 6.02 (Mar 24) to 4.16, marking a decrease of 1.86.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.36. This value is within the healthy range. It has decreased from 2.68 (Mar 24) to 0.36, marking a decrease of 2.32.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has decreased from 1.83 (Mar 24) to 0.20, marking a decrease of 1.63.
• For PBDIT Margin (%), as of Mar 25, the value is 5.25. This value is below the healthy minimum of 10. It has increased from 4.55 (Mar 24) to 5.25, marking an increase of 0.70.
• For PBIT Margin (%), as of Mar 25, the value is 4.53. This value is below the healthy minimum of 10. It has increased from 4.00 (Mar 24) to 4.53, marking an increase of 0.53.
• For PBT Margin (%), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 10. It has decreased from 1.78 (Mar 24) to 0.39, marking a decrease of 1.39.
• For Net Profit Margin (%), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 1.21 (Mar 24) to 0.22, marking a decrease of 0.99.
• For Return on Networth / Equity (%), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 1.14, marking a decrease of 9.23.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.17. This value is within the healthy range. It has decreased from 22.87 (Mar 24) to 16.17, marking a decrease of 6.70.
• For Return On Assets (%), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 5. It has decreased from 2.41 (Mar 24) to 0.25, marking a decrease of 2.16.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.42, marking a decrease of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 2.25. This value exceeds the healthy maximum of 1. It has increased from 1.71 (Mar 24) to 2.25, marking an increase of 0.54.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 2.13 (Mar 24) to 1.18, marking a decrease of 0.95.
• For Current Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 1.5. It has decreased from 1.23 (Mar 24) to 1.19, marking a decrease of 0.04.
• For Quick Ratio (X), as of Mar 25, the value is 0.32. This value is below the healthy minimum of 1. It has increased from 0.28 (Mar 24) to 0.32, marking an increase of 0.04.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.09. This value is below the healthy minimum of 4. It has decreased from 3.33 (Mar 24) to 2.09, marking a decrease of 1.24.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.27. This value is below the healthy minimum of 3. It has decreased from 2.05 (Mar 24) to 1.27, marking a decrease of 0.78.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.05. This value is below the healthy minimum of 3. It has decreased from 1.55 (Mar 24) to 1.05, marking a decrease of 0.50.
• For Enterprise Value (Cr.), as of Mar 25, the value is 66.75. It has decreased from 85.41 (Mar 24) to 66.75, marking a decrease of 18.66.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.85, marking an increase of 0.19.
• For EV / EBITDA (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 15. It has increased from 14.65 (Mar 24) to 16.27, marking an increase of 1.62.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.47 (Mar 24) to 0.44, marking a decrease of 0.03.
• For Price / BV (X), as of Mar 25, the value is 2.30. This value is within the healthy range. It has decreased from 4.05 (Mar 24) to 2.30, marking a decrease of 1.75.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.47 (Mar 24) to 0.44, marking a decrease of 0.03.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness